Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.55 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.55 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 3/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | METAP1 | P53582 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992002 | 0.88 | ACHE (0.56) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL30715530 | 0.88 | ACHE (0.56) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL31189156 | 0.84 | METAP1 (0.58) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL13039619 | 0.84 | DRD2 (0.60) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL7271049 | 0.83 | CYP24A1 (0.56) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL630841 | 0.83 | ACHE (0.58) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL2440274 | 0.81 | CYP24A1 (0.56) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL22867686 | 0.81 | CYP24A1 (0.55) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL5753017 | 0.81 | CYP24A1 (0.55) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL7519184 | 0.80 | CYP24A1 (0.54) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691861-B2 | Indolymaleimide derivatives | NOVARTIS AG (CH) | 2010-04-06 | — | — | US | disclosed |
| US-20080234494-A1 | Indolylmaleimide Derivatives | NOVARTIS AG (CH) | 2008-09-25 | — | — | US | disclosed |
| EP-1709030-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| EP-1709030-A1 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005068454-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
| EP-0163416-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-31 | — | — | EP | disclosed |
| US-4751240-A | ANTIFERTILITY AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-06-14 | — | — | US | disclosed |
| EP-0163416-A2 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234494-A1 | Indolylmaleimide Derivatives | IDH3A, INMT, IDH2 | CYP24A1 3632/4885CYP27A1 3715/4885CYP26A1 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.